Batch note: All 53 articles carry classification_confidence: medium (except two with low). No preprints are present. The overwhelming majority are review articles, meta-analyses, or case reports — only a handful represent primary prospective data. The triage agent applied a flat triage_score of 7–8 to nearly every article regardless of design quality, which my independent Phase 2 scoring corrects substantially. I have re-scored each article independently below.

---

Article-by-Article Scoring

---

Article 1 — Lou & Lyu, J Hematol Oncol 2026 (PMID 42711696)

Next-generation antibody-based therapeutics in cancer (ADCs & bispecifics)

Dimension	Score	Rationale
Scientific Novelty	6	Comprehensive synthesis of a rapidly moving field; review-level, not discovery
Clinical Relevance	7	ADCs and bispecifics are actively reshaping hematology and oncology practice
Population Reach	8	Covers hematologic + solid tumors — broad reach across cancer types
Implementation Speed	7	Many agents already FDA-approved or in late-phase trials
Evidence Strength	6	Meta-analysis/review of clinical data; no new primary data

• Key quantitative result: Not extractable from abstract; narrative synthesis
• External validation: Draws on pivotal trial data across approved agents
• Main limitation: Review design; no meta-analytic pooling of outcomes reported
• Equity implications: Access to novel antibody conjugates remains limited in LMICs and rural settings; no equity analysis noted
• Evidence Maturity: Validated (as a field-state synthesis) → Confirmed

---

Article 2 — Singh et al., Indian J Clin Biochem 2026 (PMID 42712808)

High-dose Vitamin C in Cancer: Systematic Review

Dimension	Score	Rationale
Scientific Novelty	4	High-dose IV vitamin C has been studied for decades; no new findings here
Clinical Relevance	4	Evidence remains mixed; not standard of care; no practice change signaled
Population Reach	6	Cancer broadly, but adjunctive role only
Implementation Speed	4	Protocol optimization explicitly unresolved
Evidence Strength	5	Systematic review but in a journal with limited impact; no pooled effect sizes extractable

• Key quantitative result: Not reported in abstract
• External validation: Ongoing debate; multiple prior reviews with conflicting conclusions
• Main limitation: High heterogeneity across vitamin C trials; no meta-analytic synthesis apparent
• Equity implications: IV vitamin C is relatively inexpensive but requires infusion infrastructure
• Evidence Maturity Revision: Downgrade to Exploratory — the field remains unresolved

---

Article 3 — Mansouri et al., J Am Heart Assoc 2026 (PMID 42714458)

Tirzepatide and Atrial Fibrillation: Meta-Analysis of RCTs

Dimension	Score	Rationale
Scientific Novelty	6	Important safety signal for the fastest-growing drug class in medicine
Clinical Relevance	8	Tirzepatide prescribed to millions; AF signal has immediate prescribing implications
Population Reach	9	Adults with overweight/obesity — hundreds of millions globally
Implementation Speed	7	Clinicians can modify monitoring protocols now
Evidence Strength	7	Updated meta-analysis of RCTs; "higher odds of overall arrhythmias" but low event rates — needs careful interpretation

• Key quantitative result: Higher odds ratio for arrhythmias (exact OR not extractable from abstract); event rates described as low
• External validation: Based on multiple RCTs; consistent with prior GLP-1 class signals
• Main limitation: Low absolute event rates make clinical significance uncertain; potential confounding by weight loss–mediated cardiac remodeling
• Equity implications: Tirzepatide is expensive and access-limited; safety data predominantly from clinical trial populations (often not representative of real-world diversity)
• Evidence Maturity: Validated — confirmed; though clinical significance of the arrhythmia signal remains uncertain

---

Article 4 — Macon et al., Public Health Genomics 2026 (PMID 42715123)

Engagement and Retention in Precision Public Health (Cluster RCTs)

Dimension	Score	Rationale
Scientific Novelty	5	Implementation science finding; well-recognized problem
Clinical Relevance	5	Affects research infrastructure and equity, not direct patient care
Population Reach	7	Implications for genomic research representation broadly
Implementation Speed	6	Findings applicable to trial design now
Evidence Strength	7	Two cluster RCTs — rigorous design for implementation science

• Key quantitative result: Not extractable from abstract
• Main limitation: Cascade analysis framework depends on trial-specific populations; generalizability uncertain
• Equity implications: Directly addresses equity — finding that stage-specific engagement strategies are needed to improve diversity in genomic research is the core message
• Evidence Maturity: Validated — confirmed

---

Article 5 — Subramanian et al., J Clin Oncol 2026 (PMID 42715505)

Personalized ctDNA Analysis in Sarcoma (SU2C-SARC032 Trial)

Dimension	Score	Rationale
Scientific Novelty	7	Personalized ctDNA in sarcoma is underdeveloped; embedded in a phase 2 trial
Clinical Relevance	7	Supports ctDNA-guided trial design in a cancer type with poor biomarker options
Population Reach	4	Soft-tissue sarcoma is relatively rare
Implementation Speed	5	Authors call for prospective interventional trials — not yet ready for practice
Evidence Strength	7	Analysis within a randomized trial (SU2C-SARC032); JCO publication adds credibility

• Key quantitative result: Not extractable from abstract
• External validation: Embedded in multicenter RCT; prospective design
• Main limitation: Abstract-only; STS is biologically heterogeneous; generalizability across subtypes unclear
• Equity implications: Rare cancer with limited options; ctDNA access may further disadvantage underserved patients
• Evidence Maturity: Validated — confirmed (within context of supporting future trial design)

---

Article 6 — Kleeman & Stearns, J Clin Oncol 2026 (PMID 42715513)

Risk-Adapted Neoadjuvant Therapy in HER2+ Early Breast Cancer (Review)

Dimension	Score	Rationale
Scientific Novelty	5	Risk-adapted approaches are well-established in HER2+ BC; this synthesizes recent evidence
Clinical Relevance	8	HER2+ early breast cancer is one of the most clinically active precision oncology areas
Population Reach	7	HER2+ breast cancer is the 2nd most common BC subtype globally
Implementation Speed	7	Frameworks largely implementable now with existing drugs
Evidence Strength	6	Expert review in JCO; not a meta-analysis or new primary data

• Key quantitative result: Not extractable
• Main limitation: Review design; specific ctDNA connection in abstract is tangential to core content
• Equity implications: HER2-targeted therapy access varies markedly globally; de-escalation strategies could reduce cost burden
• Evidence Maturity: Validated — confirmed

---

Article 7 — Duquesne et al., French J Urol 2026 (PMID 42716474)

Risk Stratification in Non-Muscle-Invasive Bladder Cancer

Dimension	Score	Rationale
Scientific Novelty	5	Multi-axial reassessment framework is conceptually appealing but incremental
Clinical Relevance	7	NMIBC management is actively evolving with new intravesical therapies
Population Reach	6	Bladder cancer is common globally; NMIBC is ~75% of cases
Implementation Speed	5	Framework requires development and validation before routine adoption
Evidence Strength	5	Narrative review; no primary data or meta-analysis

• Main limitation: Abstract-only; classification mislabeled as "RCT" by Phase 1 — this is a review/opinion
• Equity implications: New intravesical therapies are expensive; equity gap likely to widen
• Evidence Maturity: Exploratory (downgrade) — the proposed framework lacks prospective validation

---

Article 8 — Huang et al., Clin Genitourin Cancer 2026 (PMID 42716838)

ctDNA AR Gene Alterations in Metastatic Castration-Resistant Prostate Cancer (Meta-analysis)

Dimension	Score	Rationale
Scientific Novelty	6	AR alterations in ctDNA are a known prognostic marker; meta-analytic synthesis is useful
Clinical Relevance	7	mCRPC has expanding treatment options where AR-based biomarkers are clinically relevant
Population Reach	6	mCRPC is a significant population of metastatic prostate cancer patients
Implementation Speed	5	Authors explicitly state prospective biomarker-stratified studies still needed
Evidence Strength	6	Systematic review/meta-analysis design; abstract-only limits full assessment

• Main limitation: Need for prospective biomarker-stratified trials explicitly acknowledged; residual confounding across studies
• Equity implications: ctDNA testing access varies; predominantly studied in well-resourced trial populations
• Evidence Maturity: Validated — confirmed (for prognostic association); interventional implications still exploratory

---

Article 9 — Meza et al., Hematology 2026 (PMID 42711755)

Frontline Therapies for Ph-negative B-cell ALL: Systematic Literature Review

Dimension	Score	Rationale
Scientific Novelty	4	Safety consolidation across existing frontline therapies; no new findings
Clinical Relevance	6	Confirms safety profile of frontline targeted therapies in ALL — clinically reassuring
Population Reach	5	Adult B-cell ALL; relatively uncommon cancer
Implementation Speed	7	"No new safety signals" supports continued use of current regimens
Evidence Strength	6	Systematic review; abstract-only; design labeled as RCT incorrectly by Phase 1

• Main limitation: Safety surveillance finding; does not establish efficacy superiority
• Equity implications: Minimal discussion expected; some targeted agents have access barriers
• Evidence Maturity: Validated — confirmed

---

Article 10 — Kumari et al., Indian J Hematol Blood Transfus 2026 (PMID 42712798)

ctDNA Prognostic Value in DLBCL: Systematic Review & Meta-Analysis

Dimension	Score	Rationale
Scientific Novelty	5	ctDNA in DLBCL is well-established; this adds meta-analytic synthesis
Clinical Relevance	7	DLBCL is common; ctDNA has real potential to guide therapy decisions
Population Reach	6	DLBCL is the most common aggressive lymphoma globally
Implementation Speed	5	Not yet standard of care; validation studies ongoing
Evidence Strength	6	Meta-analysis but in a regional journal; key_finding is just the DOI — metadata issue

• Main limitation: The key_finding field contains only the DOI — substantive conclusions not extractable without full text
• Equity implications: ctDNA testing access varies by region; benefit may not reach LMICs
• Evidence Maturity: Validated — confirmed

---

Article 11 — Mustafa, Indian J Clin Biochem 2026 (PMID 42712839)

Coumarins at the Crossroads of Drug Development

Dimension	Score	Rationale
Scientific Novelty	4	Coumarins are a broad natural compound class; enzyme-targeted applications are speculative
Clinical Relevance	3	No approved precision oncology coumarin agent discussed; highly preclinical
Population Reach	5	Broad potential but entirely theoretical at this stage
Implementation Speed	2	Years from any clinical application
Evidence Strength	4	Single-author systematic review; no clinical data

• Main limitation: Single author; no clinical trial data; speculative framing
• Equity implications: If developed, natural compound-derived drugs could theoretically be low-cost
• Evidence Maturity Revision: Exploratory (downgrade from Validated)

---

Article 12 — Khabaz et al., Radiology Case Reports 2026 (PMID 42712970)

Simultaneous DOTATATE Uptake in Three Non-Neuroendocrine Pathologies

Dimension	Score	Rationale
Scientific Novelty	5	Unusual diagnostic scenario; educational for nuclear medicine/hematology
Clinical Relevance	5	Important for avoiding misdiagnosis in DOTATATE PET imaging
Population Reach	3	Case report affecting a very small subset of patients
Implementation Speed	6	Diagnostic awareness can be applied immediately
Evidence Strength	2	Case report; n=1 effectively

• Main limitation: Single case; labeled as meta-analysis by Phase 1 (incorrect — case report)
• Equity implications: Limited
• Evidence Maturity Revision: Exploratory (downgrade)

---

Article 13 — Ma et al., Chin J Cancer Res 2026 (PMID 42713037)

ctDNA-based MRD-guided Adjuvant Therapy in Solid Tumors

Dimension	Score	Rationale
Scientific Novelty	6	MRD-guided treatment is a rapidly evolving area; this reviews the landscape
Clinical Relevance	7	If validated, MRD guidance could spare patients unnecessary adjuvant therapy
Population Reach	8	Solid tumors broadly — potentially affects millions annually
Implementation Speed	5	Ongoing trials; thresholds not yet defined
Evidence Strength	5	Review article; no primary data; abstract-only

• Main limitation: Framework review; clinical benefit of MRD-guided intervention not yet proven
• Equity implications: ctDNA MRD testing is expensive; access equity is a major concern
• Evidence Maturity: Validated (as a field review) — confirmed, with intervention evidence still exploratory

---

Article 14 — Yao et al., Front Oncol 2026 (PMID 42713197)

Organ Preservation after Neoadjuvant Immunotherapy in MMR-deficient Colorectal Cancer

Dimension	Score	Rationale
Scientific Novelty	6	Watch-and-wait after immunotherapy in dMMR CRC is a genuinely emerging paradigm
Clinical Relevance	8	Organ preservation in rectal cancer is a high-priority clinical question
Population Reach	6	dMMR colorectal cancer ~15% of CRC; Lynch syndrome subset
Implementation Speed	5	Prospective validation explicitly required; ctDNA limitations noted
Evidence Strength	5	Review article; not primary data

• Main limitation: ctDNA limitations as standalone decision tool explicitly flagged; location-specific validation needed
• Equity implications: Lynch syndrome screening rates vary dramatically by geography and access
• Evidence Maturity: Validated (synthesizes existing trial data) — confirmed

---

Article 15 — Ho et al., J Pharm Pharm Sci 2026 (PMID 42713229)

Fenofibrate in Ophthalmology

Dimension	Score	Rationale
Scientific Novelty	5	Fenofibrate repurposing beyond diabetic retinopathy is plausible but established concept
Clinical Relevance	5	Adjunctive ophthalmic therapy for common conditions; not practice-changing yet
Population Reach	7	Diabetic eye disease is very common globally
Implementation Speed	4	Further RCTs explicitly required
Evidence Strength	5	Review in a pharmaceutical sciences journal; not a meta-analysis

• Main limitation: No new primary clinical data; mechanistic evidence incomplete
• Equity implications: Fenofibrate is generic and widely available — potential for equitable access
• Evidence Maturity: Exploratory (downgrade from Validated — no new evidence presented)

---

Article 16 — Zhang et al., CA Cancer J Clin 2026 (PMID 42713910)

Early-Stage NSCLC: Risk-Adaptive Paradigm in Biologic Precision Era

Dimension	Score	Rationale
Scientific Novelty	6	CA Cancer J Clin publication of a precision framework for early NSCLC carries weight
Clinical Relevance	8	Early NSCLC is a major clinical challenge; precision staging and treatment is directly relevant
Population Reach	9	Lung cancer is the leading cause of cancer death globally
Implementation Speed	6	Some elements (adjuvant targeted therapy) already in guidelines
Evidence Strength	6	Review in the highest-impact oncology journal; not primary data but synthesizes landmark trials

• Main limitation: Abstract-only; "holistic lifespan-oriented strategy" language is aspirational
• Equity implications: Equitable delivery explicitly mentioned as a goal — important framing given disparities in lung cancer screening access
• Evidence Maturity: Validated — confirmed (as synthesis in a flagship journal)

---

Article 17 — Dhanush et al., Metab Brain Dis 2026 (PMID 42714656)

Drug Repurposing for Parkinson's Disease

Dimension	Score	Rationale
Scientific Novelty	4	Drug repurposing in Parkinson's is an active but crowded field; review-level
Clinical Relevance	5	Parkinson's has significant unmet need but no repurposed agents are ready
Population Reach	7	Parkinson's affects ~10 million people globally
Implementation Speed	3	Computational/network pharmacology stage; years from clinical use
Evidence Strength	4	Review; incorrectly matched to GLP-1/cardiometabolic topic

• Main limitation: Mismatched topic assignment; no clinical data presented
• Equity implications: Drug repurposing could reduce cost barriers if successful
• Evidence Maturity Revision: Exploratory (downgrade from Validated)

---

Article 18 — Abdelrahim et al., Surg Oncol 2026 (PMID 42715861)

ctDNA and Recurrence after Curative Treatment of HCC: Meta-Analysis

Dimension	Score	Rationale
Scientific Novelty	5	ctDNA in HCC post-resection is a known question; meta-analysis adds synthesis
Clinical Relevance	6	HCC recurrence is a major clinical problem; ctDNA could guide surveillance
Population Reach	7	HCC is highly prevalent in Asia, Sub-Saharan Africa
Implementation Speed	3	"Routine use not yet supported" — explicit negative conclusion
Evidence Strength	6	Meta-analysis; abstract-only; negative/cautious conclusion

• Main limitation: Explicitly concludes routine use unsupported — most clinically honest finding in this batch
• Equity implications: HCC disproportionately affects LMICs where ctDNA access is lowest
• Evidence Maturity: Validated — confirmed (for the cautionary conclusion)

---

Article 19 — Gholap et al., Drug Discov Today 2026 (PMID 42716205)

Effector-cell-engaging Bispecific Antibodies for Cancer

Dimension	Score	Rationale
Scientific Novelty	6	NK/macrophage-engaging bsAbs and trispecifics are genuinely emerging
Clinical Relevance	6	Some agents clinically validated; others early-stage
Population Reach	7	Multiple cancer types covered
Implementation Speed	4	Preclinical stage for novel formats
Evidence Strength	4	Review/validation study; Exploratory maturity confirmed

• Evidence Maturity: Exploratory — confirmed

---

Article 20 — Papanikas et al., J Theor Biol 2026 (PMID 42716465)

Brain Cancer In Silico Modelling — Roadmap

Dimension	Score	Rationale
Scientific Novelty	5	Computational tumor modeling has a long history; this is a roadmap, not a result
Clinical Relevance	3	Distant from patient care; mechanistic gap acknowledged
Population Reach	6	Brain tumors have high unmet need; but this is very early-stage
Implementation Speed	2	Many years from clinical impact
Evidence Strength	3	Review article only

• Evidence Maturity Revision: Exploratory — confirmed

---

Article 21 — Barrett et al., ANZ J Surg 2026 (PMID 42716724)

27-Year Single-Centre Splenectomy Outcomes

Dimension	Score	Rationale
Scientific Novelty	4	Laparoscopic splenectomy outcomes are well-documented
Clinical Relevance	6	Useful long-term data for counseling patients pre-splenectomy
Population Reach	4	Relatively uncommon procedure
Implementation Speed	7	Already in practice; data reinforces current approach
Evidence Strength	5	Single-centre 27-year retrospective; systematic review label is inaccurate

• Evidence Maturity: Validated — confirmed (practice-confirming rather than changing)

---

Article 22 — Ebrahimi et al., Heart Lung Circ 2026 (PMID 42716866)

ViV-TAVR vs. Surgical Redo for Degenerated Bioprosthetic Aortic Valve

Dimension	Score	Rationale
Scientific Novelty	5	ViV-TAVR vs. redo surgery comparison has been studied; updated propensity-matched analysis
Clinical Relevance	7	Common clinical decision for structural heart disease teams
Population Reach	6	Aging population with prior valve replacement — growing cohort
Implementation Speed	6	Data immediately applicable to patient selection discussions
Evidence Strength	6	Meta-analysis of propensity-score-matched studies; inherent selection bias concerns

• Main limitation: Higher post-procedural gradients after ViV-TAVR is a real clinical concern; need for RCTs explicitly acknowledged
• Equity implications: TAVR access varies by institution and geography
• Evidence Maturity: Validated — confirmed

---

Article 23 — Chen & Bao, Int J Equity Health 2026 (PMID 42711697)

Aging Caregivers for Adults with Schizophrenia in Rural China

Dimension	Score	Rationale
Scientific Novelty	4	Well-recognized social problem; qualitative documentation
Clinical Relevance	4	Policy/social care relevance; not directly clinical
Population Reach	6	Large rural elderly caregiver population in China and similar settings
Implementation Speed	4	Policy change is slow
Evidence Strength	5	Qualitative life-course study; labeled as meta-analysis incorrectly by Phase 1

• Equity implications: Strong equity focus — core finding is about unfair burden distribution
• Evidence Maturity: Validated — confirmed (for qualitative evidence)

---

Article 24 — Marei et al., Stem Cell Res Ther 2026 (PMID 42711726)

Advances in CAR-T Molecular Mechanisms for Viral, Cancer, and Autoimmune Diseases

Dimension	Score	Rationale
Scientific Novelty	6	Expansion of CAR-T beyond oncology is genuinely novel territory
Clinical Relevance	5	Autoimmune applications early-stage; oncology applications established
Population Reach	8	Autoimmune diseases + cancer = enormous population
Implementation Speed	3	Manufacturing scalability explicitly identified as barrier
Evidence Strength	4	Review article; Exploratory maturity confirmed

• Evidence Maturity: Exploratory — confirmed

---

Article 25 — Darvishi et al., Future Sci OA 2026 (PMID 42712115)

Botulinum Toxin Injection Techniques in Chronic Plantar Fasciitis (RCT)

Dimension	Score	Rationale
Scientific Novelty	5	Injection technique comparison; Babcock method functional advantage at longer term
Clinical Relevance	5	Common musculoskeletal condition; practical for MSK practitioners
Population Reach	6	Plantar fasciitis is extremely common
Implementation Speed	6	Injection technique adaptable now if training available
Evidence Strength	6	RCT design; abstract-only; sample size unknown

• Evidence Maturity: Validated — confirmed

---

Article 26 — Soonu et al., J Pathol Transl Med 2026 (PMID 42712222)

Obesity-driven Adipokine Signaling in Breast Cancer

Dimension	Score	Rationale
Scientific Novelty	5	Obesity-cancer interactions are well-studied; mechanistic review
Clinical Relevance	4	No therapeutic readiness; mechanistic synthesis
Population Reach	8	Obesity + breast cancer overlap is enormous globally
Implementation Speed	2	Entirely preclinical at this stage
Evidence Strength	3	Review; Exploratory confirmed

• Evidence Maturity: Exploratory — confirmed

---

Article 27 — Nayak et al., Lupus 2026 (PMID 42712258)

Metabolic Syndrome Prevalence in SLE: Meta-Analysis

Dimension	Score	Rationale
Scientific Novelty	4	MetS in SLE is a known association; global prevalence pooling adds modest value
Clinical Relevance	6	Highlights need for cardiometabolic monitoring in SLE patients
Population Reach	5	SLE predominantly affects women of reproductive age; significant global burden
Implementation Speed	6	Monitoring recommendations already implementable
Evidence Strength	6	Meta-analysis; abstract-only; large author list (21 authors)

• Equity implications: SLE disproportionately affects women of color; cardiometabolic risk monitoring equity is important
• Evidence Maturity: Validated — confirmed

---

Article 28 — Ho et al., Afr J Emerg Med 2026 (PMID 42713255)

Intubation Kits and Checklists in Rwanda (RCT)

Dimension	Score	Rationale
Scientific Novelty	5	Structured airway management in LMICs is pragmatically important
Clinical Relevance	6	First-pass intubation success is directly life-saving
Population Reach	6	LMIC emergency settings broadly applicable
Implementation Speed	7	Checklist/kit approach is low-cost and scalable
Evidence Strength	6	RCT in Rwanda — study calls for larger confirmatory study

• Equity implications: Strong — directly addresses emergency care quality in resource-limited settings
• Evidence Maturity: Validated — confirmed (pilot-level; needs replication)

---

Article 29 — Balint et al., JACC 2026 (PMID 42714046)

Genetic Determinants of Heart Failure in HLHS (NC-DEFINE Study)

Dimension	Score	Rationale
Scientific Novelty	7	Genetics of myocardial vulnerability in HLHS is underdeveloped; prospective multicenter design
Clinical Relevance	6	Could enable risk stratification in a uniformly high-risk population
Population Reach	4	HLHS is rare (~1 per 4,000 live births); but Population Reach score elevated for unmet need
Implementation Speed	3	Exploratory; genetic screening infrastructure for neonates required
Evidence Strength	6	Prospective multicenter JACC publication; abstract-only; Exploratory maturity

• Equity implications: Congenital heart disease outcomes have significant racial and socioeconomic disparities
• Evidence Maturity: Exploratory — confirmed

---

Article 30 — Hegzay et al., Curr Cardiol Rep 2026 (PMID 42714692)

MASLD and 35% Higher Risk of HFpEF: Meta-Analysis

Dimension	Score	Rationale
Scientific Novelty	6	35% higher HFpEF risk is a quantifiable and clinically meaningful finding
Clinical Relevance	7	HFpEF is common and poorly treated; MASLD link supports integrated cardiometabolic care
Population Reach	8	MASLD affects ~25% of adults globally; HFpEF is highly prevalent
Implementation Speed	5	Monitoring implementable; GLP-1 agonist trials warranted but pending
Evidence Strength	6	Systematic review/meta-analysis; key_finding field truncated (metadata issue)

• Key quantitative result: 35% higher risk of HFpEF associated with MASLD
• Main limitation: Metadata truncation makes full assessment difficult; confounding likely in observational studies
• Equity implications: MASLD disproportionately affects lower-SES populations; HFpEF care is resource-intensive
• Evidence Maturity: Validated — confirmed

---

Article 31 — Geis et al., PLoS One 2026 (PMID 42715227)

Seminal Fluid cfDNA Methylation for Prostate Cancer Detection

Dimension	Score	Rationale
Scientific Novelty	7	Seminal fluid as a liquid biopsy medium is genuinely novel
Clinical Relevance	6	Prostate cancer detection is a major clinical challenge; non-invasive approach appealing
Population Reach	7	Prostate cancer is the most common non-skin cancer in men
Implementation Speed	3	Proof-of-concept; clinical validation pipeline long
Evidence Strength	5	Observational cohort; abstract-only; PLoS One publication

• Main limitation: Observational feasibility study; no diagnostic accuracy metrics extractable; limited to men capable of producing ejaculate
• Equity implications: Non-invasive test could improve access; but requires further development
• Evidence Maturity: Exploratory — confirmed

---

Article 32 — Nguyen et al., JCO Precis Oncol 2026 (PMID 42715508)

Prospective ctDNA Evaluation in Metastatic Hormone-Sensitive Prostate Cancer

Dimension	Score	Rationale
Scientific Novelty	6	Prospective ctDNA in mHSPC with diverse cohort adds to a growing evidence base
Clinical Relevance	7	Baseline ctDNA positive status associated with worse outcomes — directly actionable for risk stratification
Population Reach	6	mHSPC is a significant and growing population
Implementation Speed	5	Needs prospective validation; complementary to existing tools
Evidence Strength	6	Multicenter prospective observational; abstract-only

• Key quantitative result: Positive ctDNA tumor fraction at baseline associated with worse outcomes in mHSPC
• Equity implications: Diverse cohort is a notable strength for generalizability
• Evidence Maturity: Exploratory (downgrade from listed — prospective observational, not interventional) → revise to Exploratory

---

Article 33 — Mouhieddine & Anderson, NEJM 2026 (PMID 42715563)

Treatment Decisions in Multiple Myeloma (NEJM Review)

Dimension	Score	Rationale
Scientific Novelty	5	State-of-the-art synthesis; NEJM audience-facing
Clinical Relevance	8	Multiple myeloma therapy is extremely active; NEJM review will shape clinical practice
Population Reach	6	Multiple myeloma is the 2nd most common hematologic malignancy
Implementation Speed	7	Synthesizes currently available agents
Evidence Strength	6	Expert review in NEJM; not primary data but draws on landmark trials

• Main limitation: Abstract-only; review design
• Equity implications: Novel myeloma agents (quad-drug regimens, bispecifics) are very expensive; global access is limited
• Evidence Maturity: Validated — confirmed (as field synthesis)

---

Article 34 — Liu et al., Neurobiol Dis 2026 (PMID 42716230)

MicroRNAs in Polyglutamine Diseases

Dimension	Score	Rationale
Scientific Novelty	6	miRNA-based therapeutics for PolyQ disorders (HD, SCA) are genuinely exploratory
Clinical Relevance	4	No approved miRNA therapies yet; early mechanistic stage
Population Reach	4	PolyQ diseases are rare; Huntington's most prominent
Implementation Speed	2	Many years from clinical use
Evidence Strength	4	Review; observational cohort label in Phase 1 appears inaccurate

• Evidence Maturity: Exploratory — confirmed

---

Article 35 — Abuhassan et al., Clin Chim Acta 2026 (PMID 42716240)

Phage-based Biosensors for Cancer Biomarker Detection

Dimension	Score	Rationale
Scientific Novelty	6	Phage-display biosensors are an emerging detection platform
Clinical Relevance	4	Pre-clinical; clinical validation explicitly lacking
Population Reach	7	Broad cancer early detection potential
Implementation Speed	2	Pre-clinical technology
Evidence Strength	3	Review; no clinical data

• Evidence Maturity: Exploratory — confirmed

---

Article 36 — Fang et al., Cancer Lett 2026 (PMID 42716420)

Tumor Vasculature in Cancer Immunotherapy Era

Dimension	Score	Rationale
Scientific Novelty	5	Vascular normalization + immunotherapy combination is an established concept
Clinical Relevance	5	Combination strategies exist but evidence is early-stage
Population Reach	7	Solid tumors broadly
Implementation Speed	3	Preclinical; combination strategies need trial validation
Evidence Strength	3	Review; no primary data

• Evidence Maturity: Exploratory — confirmed

---

Article 37 — Grasso et al., Pediatrics 2026 (PMID 42716532)

CAR-T Therapy in Pediatric ALL — Review for General Pediatricians

Dimension	Score	Rationale
Scientific Novelty	4	Tisagenlecleucel is FDA-approved; this is an educational review for generalists
Clinical Relevance	8	Critical guidance for general pediatricians managing children post-CAR-T
Population Reach	5	Pediatric ALL is relatively uncommon but devastating
Implementation Speed	8	CAR-T is already in practice; shared-care guidance immediately usable
Evidence Strength	5	Narrative review in Pediatrics; clinical utility is its value

• Equity implications: CAR-T access is dramatically unequal globally; even in high-income countries, center availability is limited
• Evidence Maturity: Validated — confirmed (for practice guidance purposes)

---

Article 38 — Abdwani et al., Lupus Sci Med 2026 (PMID 42716676)

DNASE1L3 Deficiency: Multicenter Longitudinal Cohort

Dimension	Score	Rationale
Scientific Novelty	6	Ultra-rare monogenic lupus; disease activity/outcome discordance is a novel observation
Clinical Relevance	6	Directly affects management decisions in DNASE1L3-deficient patients
Population Reach	3	Ultra-rare disease; very small population
Implementation Speed	4	Small cohort; cautious interpretation explicitly required
Evidence Strength	5	Multicenter longitudinal; small n acknowledged as limitation

• Equity implications: Rare diseases disproportionately affect underserved populations who lack diagnostic access
• Evidence Maturity: Exploratory — confirmed

---

Article 39 — Salim et al., AJNR 2026 (PMID 42716711)

MRI Radiomics for Survival Prediction in Brain Metastases

Dimension	Score	Rationale
Scientific Novelty	5	Radiomics for brain metastases survival is an active research area
Clinical Relevance	5	"Cautious use" as exploratory biomarker — modest clinical readiness
Population Reach	6	Brain metastases affect ~200,000 patients/year in the US alone
Implementation Speed	4	Needs integrated prognostic models; not standalone
Evidence Strength	5	Observational cohort; abstract-only; radiomics reproducibility is a known concern

• Evidence Maturity: Exploratory — confirmed

---

Article 40 — Obinah et al., Acta Oncol 2026 (PMID 42714248)

Pre-operative ctDNA in High-Risk Cutaneous Melanoma

Dimension	Score	Rationale
Scientific Novelty	6	ctDNA in primary (pre-metastatic) melanoma is understudied
Clinical Relevance	5	Honest negative/inconclusive finding; standard mutation-based ctDNA unreliable pre-op
Population Reach	6	Melanoma incidence rising globally
Implementation Speed	3	Explicit conclusion that alternative cfDNA methods needed
Evidence Strength	5	Prospective feasibility study; abstract-only

• Main limitation: Current methods insufficient; negative feasibility finding
• Evidence Maturity: Exploratory — confirmed

---

Article 41 — Carrasco-Zanini et al., Sci Transl Med 2026 (PMID 42715344)

Proteomics Identify Disease-Associated Variants in Undiagnosed Rare Diseases

Dimension	Score	Rationale
Scientific Novelty	8	Serum proteomics as a complement to genome sequencing for rare disease diagnosis is highly novel
Clinical Relevance	7	Directly benefits patients who remain undiagnosed after WGS — a genuine unmet need
Population Reach	5	Rare disease patients broadly; higher relative to this specific population's unmet need
Implementation Speed	4	Proof-of-principle; platform coverage and sensitivity gaps acknowledged
Evidence Strength	6	Science Translational Medicine publication; proof-of-principle; not yet validated at scale

• Key quantitative result: Proof-of-principle demonstrated; success rate not extractable from abstract
• Main limitation: Tissue specificity, blood detectability, and platform sensitivity are explicit constraints
• Equity implications: Rare disease diagnostic odyssey disproportionately burdens underserved populations; proteomics could democratize diagnosis
• Evidence Maturity: Exploratory — confirmed (though methodologically promising)

---

Article 42 — Gilbert et al., Hum Pathol 2026 (PMID 42716382)

Sarcomatoid Malignancies with Strong PD-L1 Expression: Dedifferentiated Melanoma

Dimension	Score	Rationale
Scientific Novelty	6	Diagnostic pitfall identification with therapeutic implications (ICI eligibility)
Clinical Relevance	6	PD-L1 IHC as diagnostic/therapeutic tool; directly affects immunotherapy eligibility
Population Reach	3	Uncommon diagnostic scenario
Implementation Speed	6	PD-L1 IHC is widely available; diagnostic awareness can be applied immediately
Evidence Strength	5	Observational cohort; abstract-only

• Evidence Maturity: Exploratory — confirmed

---

Article 43 — Wang et al., J Immunother Cancer 2026 (PMID 42716706)

PRKX-mediated PD-L1 Stabilization in Gastric Cancer

Dimension	Score	Rationale
Scientific Novelty	7	PRKX as a novel PD-L1 stabilizer and therapeutic target is new
Clinical Relevance	4	Mixed (human/animal) model; not yet clinical
Population Reach	6	Gastric cancer is the 5th most common cancer globally
Implementation Speed	3	Preclinical target; years from clinical use
Evidence Strength	4	Mixed species; observational; abstract-only

• Clinical Relevance cap applied: Non-human components → capped at 5 maximum
• Evidence Maturity: Exploratory — confirmed

---

Article 44 — Toledano et al., Bull Cancer 2026 (PMID 42716872)

Oncogenetics and Molecular Tumor Boards in Private Practice (French)

Dimension	Score	Rationale
Scientific Novelty	4	Coordination of constitutional and tumor genetics is an organizational/systems finding
Clinical Relevance	5	Integration of germline + somatic genetics improves decision-making
Population Reach	5	Private practice oncogenetics in France; limited generalizability
Implementation Speed	5	Organizational model could be adapted
Evidence Strength	3	Exploratory/observational; no primary data; French-language abstract

• Evidence Maturity: Exploratory — confirmed

---

Article 45 — Nievas et al., Med Intensiva 2026 (PMID 42716890)

Immunotherapy in Critically Ill Cancer Patients — ICU Review

Dimension	Score	Rationale
Scientific Novelty	5	irAE management in the ICU is increasingly clinically relevant
Clinical Relevance	7	Intensivists frequently encounter immunotherapy-related critical illness; practical guidance value
Population Reach	6	Growing immunotherapy use means growing ICU encounters
Implementation Speed	6	Educational; directly applicable to ICU practice
Evidence Strength	3	Observational/exploratory design; no primary data

• Evidence Maturity: Exploratory — confirmed

---

Article 46 — Yang et al., Hum Vaccines Immunother 2026 (PMID 42714310)

Sintilimab-related Cystitis/Ureteritis: Case Report

Dimension	Score	Rationale
Scientific Novelty	5	Rare irAE documentation; urological irAEs are underrecognized
Clinical Relevance	5	Practical reference for rare but serious complication
Population Reach	2	Very rare complication
Implementation Speed	5	Awareness can be applied now
Evidence Strength	2	Case report + literature review

• Evidence Maturity: Exploratory — confirmed

---

Article 47 — Gao et al., Sci Adv 2026 (PMID 42715308)

TLS Heterogeneity in Intrahepatic Cholangiocarcinoma

Dimension	Score	Rationale
Scientific Novelty	7	Spatiotemporal TLS mapping in iCCA with immunotherapy implications is genuinely novel
Clinical Relevance	5	Science Advances publication; insights for future stroma-directed immunotherapy
Population Reach	5	iCCA has rising incidence; significant unmet need
Implementation Speed	3	Basic science finding; translational pathway long
Evidence Strength	5	Observational/exploratory in Science Advances; no abstract available

• Evidence Maturity: Exploratory — confirmed

---

Article 48 — Cheng et al., Sci Adv 2026 (PMID 42715334)

TCR-JANUS Engager Proteins for TCR-T Cell Therapy (Preclinical)

Dimension	Score	Rationale
Scientific Novelty	7	Bispecific TCR-engager platform to overcome antigen heterogeneity is genuinely innovative
Clinical Relevance	3	Preclinical only; cap applies
Population Reach	6	Solid tumor T-cell therapy — large unmet need
Implementation Speed	2	Preclinical; first-in-human trials years away
Evidence Strength	4	Preclinical experimental; no abstract available

• Evidence Maturity: Exploratory — confirmed

---

Article 49 — Ammar et al., Neurol Neuroimmunol Neuroinflammation 2026 (PMID 42715496)

Daratumumab in Severe Anti-NMDAR Encephalitis: Case Reports

Dimension	Score	Rationale
Scientific Novelty	7	Daratumumab for anti-NMDAR encephalitis is a genuinely novel repurposing
Clinical Relevance	6	Severe anti-NMDAR encephalitis has limited salvage options
Population Reach	3	Rare neurological emergency
Implementation Speed	4	Evidence limited to case reports; timing/safety unresolved
Evidence Strength	3	Case reports only; authors explicitly state evidence is limited

• Equity implications: Anti-NMDAR encephalitis is underdiagnosed in LMICs; daratumumab access is restricted
• Evidence Maturity: Exploratory — confirmed

---

Article 50 — Eschen & Mehrotra, Diagn Cytopathol 2026 (PMID 42716509)

Hematologic Malignancies Identified Through Thyroid FNA

Dimension	Score	Rationale
Scientific Novelty	5	Unusual diagnostic scenario; ROSE and hematopathology collaboration highlighted
Clinical Relevance	5	Educational for pathologists and clinicians
Population Reach	2	Very uncommon diagnostic scenario
Implementation Speed	6	Diagnostic practice guidance immediately applicable
Evidence Strength	2	Case report

• Evidence Maturity: Exploratory — confirmed

---

Article 51 — Sejrsen et al., BMJ Case Rep 2026 (PMID 42716692)

FDG PET/CT-Visualised Immune-related Hepatitis after ICI Combination

Dimension	Score	Rationale
Scientific Novelty	5	Imaging of irAE hepatitis is clinically useful documentation
Clinical Relevance	6	Fatal irAE; awareness is directly protective
Population Reach	4	Rare complication of increasingly common therapy
Implementation Speed	7	PET/CT liver assessment awareness can be applied immediately
Evidence Strength	2	Single case report

• Evidence Maturity: Exploratory — confirmed

---

Article 52 — Raschio et al., Neurol Sci 2026 (PMID 42711582)

BRAF V600E Pleomorphic Xanthoastrocytoma with Liquid Biopsy Monitoring (classification_confidence: low)

Dimension	Score	Rationale
Scientific Novelty	4	BRAF/MEK inhibition in PXA is established; liquid biopsy monitoring is the novel element
Clinical Relevance	4	Letter-level evidence; no abstract; scores reduced for low confidence
Population Reach	2	Rare brain tumor
Implementation Speed	3	Case-level; limited generalizability
Evidence Strength	2	Letter/case report; low classification confidence; no abstract

• Evidence Maturity: Exploratory — confirmed

---

Article 53 — Steffin et al., NEJM 2026 (PMID 42715569)

Complete Regression of Hepatoblastoma after IL-15/IL-21-Coexpressing CAR T-Cell Therapy (classification_confidence: low; title-only)

Dimension	Score	Rationale
Scientific Novelty	8	IL-15/IL-21 cytokine co-expression in CAR-T to overcome immunosuppression is cutting-edge
Clinical Relevance	6	Hepatoblastoma is a pediatric cancer with limited salvage options; NEJM letter suggests striking result
Population Reach	4	Hepatoblastoma is rare; but relative to the population, unmet need is high
Implementation Speed	3	Proof-of-concept case; manufacturing complexity; years from broad access
Evidence Strength	4	NEJM letter; title-only; low classification confidence — cannot score higher without abstract

• Key finding (inferred from title): Complete tumor regression in hepatoblastoma following cytokine-armored CAR-T therapy
• Main limitation: No abstract; low confidence classification; single or very few cases
• Equity implications: CAR-T in pediatric hepatoblastoma would likely remain highly specialized and access-limited for many years
• Evidence Maturity: Exploratory — confirmed; watchlist priority despite low evidence level

---

Conflict Detection

Conflicting signals within the batch:

• ctDNA utility: Multiple articles present conflicting conclusions. Abdelrahim et al. explicitly concludes ctDNA is not yet ready for routine HCC post-resection monitoring. Subramanian et al. supports ctDNA-guided trial design in sarcoma. Yao et al. flags ctDNA limitations as a standalone tool in colorectal organ preservation. This reflects the field's genuine heterogeneity — ctDNA utility is cancer-type and context-dependent; no single conclusion applies universally.
• Tirzepatide cardiac safety: Mansouri et al. raises an arrhythmia signal with low absolute rates — this is a nuanced safety finding, not a contraindication, and contrasts with the generally favorable cardiovascular profile of GLP-1/GIP class drugs from major RCTs (SELECT, SURMOUNT-OSA).

---

Composite Impact Score Table

Formula: Clinical Relevance (30%) + Population Reach (25%) + Scientific Novelty (20%) + Implementation Speed (15%) + Evidence Strength (10%)

Rank	Article (PMID)	Flag	Impact Score	Clin. Rel. (30%)	Pop. Reach (25%)	Sci. Nov. (20%)	Impl. Speed (15%)	Evid. Str. (10%)	Triage Score (OpenClaw)	Study Design
1	Mansouri et al. — Tirzepatide & AF (42714458)	🟢	7.55	8	9	6	7	7	8	Meta-analysis of RCTs
2	Zhang et al. — Early-Stage NSCLC (42713910)	🔴	7.45	8	9	6	6	6	7	Review (CA Cancer J Clin)
3	Lou & Lyu — ADCs & Bispecifics (42711696)	🟢	7.10	7	8	6	7	6	8	Review/Meta-analysis
4	Kleeman & Stearns — HER2+ Breast CA Neoadjuvant (42715513)	🟢	7.05	8	7	5	7	6	8	Review (JCO)
5	Mouhieddine & Anderson — Multiple Myeloma Tx (42715563)	🟠	6.95	8	6	5	7	6	6	Review (NEJM)
6	Hegzay et al. — MASLD & HFpEF (42714692)	⚪	6.85	7	8	6	5	6	6	Meta-analysis
7	Subramanian et al. — ctDNA in Sarcoma (SU2C) (42715505)	🔴	6.55	7	4	7	5	7	8	RCT-embedded analysis
8	Yao et al. — Organ Preservation in dMMR CRC (42713197)	🔴	6.50	8	6	6	5	5	7	Review
9	Carrasco-Zanini et al. — Proteomics for Rare Disease Dx (42715344)	⚪	6.45	7	5	8	4	6	5	Exploratory study (Sci Transl Med)
10	Grasso et al. — CAR-T in Pediatric ALL (42716532)	🟠	6.40	8	5	4	8	5	6	Review (Pediatrics)
11	Nievas et al. — Immunotherapy in ICU Patients (42716890)	🟠	6.15	7	6	5	6	3	5	Exploratory review
12	Huang et al. — ctDNA AR Alterations in mCRPC (42716838)	🔴	6.10	7	6	6	5	6	8	Meta-analysis
13	Ebrahimi et al. — ViV-TAVR vs. Surgical Redo (42716866)	🟢	6.10	7	6	5	6	6	7	Meta-analysis
14	Ma et al. — ctDNA MRD-guided Adjuvant Tx (42713037)	🔴	6.05	7	8	6	5	5	7	Review
15	Steffin et al. — CAR-T Complete Regression in Hepatoblastoma (42715569) 🚨Watchlist	🟠	5.90	6	4	8	3	4	3	NEJM Letter (title-only)
16	Macon et al. — Precision Public Health Engagement (42715123)	🟢	5.85	5	7	5	6	7	8	Cluster RCT
17	Marei et al. — CAR-T Advances Beyond Oncology (42711726)	⚪	5.75	5	8	6	3	4	6	Review
18	Meza et al. — Frontline Ph-neg B-cell ALL Tx (42711755)	🟢	5.70	6	5	4	7	6	7	Systematic review
19	Gholap et al. — Effector-cell-engaging bsAbs (42716205)	⚪	5.65	6	7	6	4	4	7	Review/validation
20	Kumari et al. — ctDNA in DLBCL (42712798)	🔴	5.65	7	6	5	5	6	7	Meta-analysis
21	Nguyen et al. — ctDNA in Metastatic HSPC (42715508)	🔴	5.65	7	6	6	5	6	6	Prospective multicenter observational
22	Balint et al. — Genetics of HLHS Heart Failure (JACC) (42714046)	⚪	5.55	6	4	7	3	6	6	Prospective multicenter cohort
23	Geis et al. — Seminal Fluid cfDNA for Prostate Cancer (42715227)	🔴	5.50	6	7	7	3	5	6	Observational cohort
24	Abdwani et al. — DNASE1L3 Deficiency Cohort (42716676)	⚪	5.30	6	3	6	4	5	6	Multicenter cohort
25	Abdelrahim et al. — ctDNA in HCC Recurrence (42715861)	🔴	5.30	6	7	5	3	6	7	Meta-analysis
26	Nayak et al. — MetS Prevalence in SLE (42712258)	⚪	5.25	6	5	4	6	6	6	Meta-analysis
27	Gao et al. — TLS Heterogeneity in iCCA (42715308)	🟠	5.20	5	5	7	3	5	4	Observational/exploratory (Sci Adv)
28	Cheng et al. — TCR-JANUS Engagers (Preclinical) (42715334)	🟠	5.10	3	6	7	2	4	4	Preclinical experimental
29	Gilbert et al. — PD-L1 in Sarcomatoid Melanoma (42716382)	🟠	5.05	6	3	6	6	5	5	Observational cohort
30	Darvishi et al. — Botulinum Toxin in Plantar Fasciitis (RCT) (42712115)	⚪	5.00	5	6	5	6	6	6	RCT
31	Wang et al. — PRKX/PD-L1 in Gastric Cancer (42716706)	🟠	4.90	4	6	7	3	4	5	Mixed-species observational
32	Fang et al. — Tumor Vasculature + Immunotherapy (42716420)	🟠	4.85	5	7	5	3	3	6	Review
33	Ho et al. — Intubation Kits in Rwanda (RCT) (42713255)	🟡	4.85	6	6	5	7	6	6	RCT
34	Ammar et al. — Daratumumab in Anti-NMDAR Encephalitis (42715496)	🟠	4.75	6	3	7	4	3	4	Case reports
35	Salim et al. — MRI Radiomics in Brain Metastases (42716711)	⚪	4.70	5	6	5	4	5	6	Observational cohort
36	Hegzay et al. — MASLD (beyond liver) (42714692)	⚪	see rank 6	—	—	—	—	—	—	—
37	Geis et al. — Seminal cfDNA prostate	🔴	see rank 23	—	—	—	—	—	—	—
38	Ho et al. — Fenofibrate in Ophthalmology (42713229)	🟢	4.65	5	7	5	4	5	7	Review
39	Marei CAR-T	⚪	see rank 17	—	—	—	—	—	—	—
40	Liu et al. — miRNAs in PolyQ Diseases (42716230)	⚪	4.55	4	4	6	2	4	6	Review
41	Obinah et al. — ctDNA in Primary Melanoma (42714248)	🔴	4.55	5	6	6	3	5	5	Prospective observational
42	Abdwani DNASE1L3	⚪	see rank 24	—	—	—	—	—	—	—
43	Abuhassan et al. — Phage Biosensors (42716240)	🔴	4.45	4	7	6	2	3	6	Review
44	Papanikas et al. — Brain Cancer In Silico (42716465)	⚪	4.15	3	6	5	2	3	7	Review
45	Barrett et al. — Splenectomy 27-year Study (42716724)	🟢	4.15	6	4	4	7	5	7	Retrospective single-centre
46	Soonu et al. — Obesity Adipokines in Breast Cancer (42712222)	⚪	4.10	4	8	5	2	3	6	Review
47	Nayak et al. MetS SLE	⚪	see rank 26	—	—	—	—	—	—	—
48	Dhanush et al. — Parkinson's Repurposing (42714656)	🟢	4.05	5	7	4	3	4	7	Review
49	Toledano et al. — Oncogenetics in Private Practice (42716872)	🔴	4.00	5	5	4	5	3	5	Exploratory
50	Gao et al. TLS iCCA	🟠	see rank 27	—	—	—	—	—	—	—
51	Sejrsen et al. — PET/CT Immune Hepatitis (42716692)	🟠	3.95	6	4	5	7	2	4	Case report
52	Chen & Bao — Aging Caregivers China (42711697)	🟡	3.90	4	6	4	4	5	6	Qualitative cohort
53	Mustafa — Coumarins Drug Development (42712839)	🟢	3.85	3	5	4	2	4	7	Systematic review
54	Khabaz et al. — DOTATATE Uptake Case Report (42712970)	🟢	3.80	5	3	5	6	2	7	Case report
55	Raschio et al. — BRAF PXA Liquid Biopsy Letter (42711582)	🔴	3.70	4	2	4	3	2	3	Letter/case
56	Yang et al. — Sintilimab-related Cystitis (42714310)	🟠	3.65	5	2	5	5	2	4	Case report
57	Eschen & Mehrotra — Hematologic Malignancies via Thyroid FNA (42716509)	🟠	3.60	5	2	5	6	2	4	Case report

⚠️ Special watchlist flag — Article 53 (PMID 42715569): Despite ranking 15th overall and having title-only data, Steffin et al. in NEJM — reporting complete regression of hepatoblastoma with IL-15/IL-21-coexpressing CAR-T — warrants immediate attention when the full letter becomes accessible. Complete regression in this setting would be clinically remarkable.

---

Top 5 Rank Justifications

Rank 1 — Mansouri et al., Tirzepatide & AF 🟢 This meta-analysis of RCTs addresses a cardinal safety question for one of the most widely prescribed drug classes in medicine. Tirzepatide (Mounjaro/Zepbound) is being used in tens of millions of patients globally for obesity and type 2 diabetes. The finding of higher odds of overall arrhythmias — even with low absolute event rates — is immediately relevant to prescribers, cardiologists, and regulators. The RCT evidence base makes this the most rigorously supported finding in the batch. Clinicians can and should incorporate this signal into monitoring discussions with high-risk patients (those with pre-existing arrhythmia susceptibility) today. Why it matters: A modest but real arrhythmia signal in a blockbuster drug class could affect monitoring guidelines for hundreds of millions of patients.

Rank 2 — Zhang et al., Early-Stage NSCLC, CA Cancer J Clin 🔴 Published in the highest-impact oncology journal (CA Cancer Journal for Clinicians), this risk-adaptive precision framework for early-stage NSCLC synthesizes adjuvant targeted therapy, immunotherapy, ctDNA monitoring, and equity considerations into a lifespan-oriented model. Lung cancer kills more people than any other cancer globally; early-stage management is where cure is achievable. The journal's imprimatur signals guideline-level influence. Why it matters: This framework could reshape how clinicians stratify and treat the growing number of early NSCLC patients identified through CT screening programs.

Rank 3 — Lou & Lyu, ADCs & Bispecifics, J Hematol Oncol 🟢 The Journal of Hematology & Oncology is a high-impact open-access journal. This synthesis covers the most transformative shift in cancer pharmacology in the past decade — the convergence of ADCs and bispecific antibodies across hematologic and solid tumors. With multiple agents (trastuzumab deruxtecan, blinatumomab, teclistamab, talquetamab, etc.) already approved and many more in late-phase trials, this roadmap directly informs precision oncology practice. Why it matters: Oncologists navigating a rapidly expanding armamentarium of antibody-based therapeutics need synthesis tools; this provides that across tumor types.

Rank 4 — Kleeman & Stearns, HER2+ Early Breast Cancer, JCO 🟢 A JCO review on risk-adapted neoadjuvant therapy in HER2-positive early breast cancer — covering de-escalation (pertuzumab omission, T-DM1 substitution) and escalation strategies — is directly practice-relevant for one of the most actively managed breast cancer subtypes. HER2+ breast cancer affects ~15–20% of all breast cancer patients (hundreds of thousands annually); individualized treatment planning using pathologic complete response and ctDNA is increasingly the standard discussion. Why it matters: De-escalation strategies reduce toxicity and cost without sacrificing cure rates — a directly patient-beneficial advance.

Rank 5 — Mouhieddine & Anderson, Multiple Myeloma Tx, NEJM 🟠 An NEJM review article on multiple myeloma treatment decisions by Kenneth Anderson (a leading global myeloma expert) carries extraordinary clinical influence. With quadruplet induction, bispecific antibodies, CAR-T, and MRD-guided therapy all now in play, treatment decisions in myeloma have become genuinely complex. This synthesis will shape how hematologists around the world approach newly diagnosed and relapsed myeloma. Why it matters: The NEJM reach ensures this review will influence clinical behavior at community hospitals, not just academic centers.

---

PHASE 4 — Deep Dives

---

[HOOK]

Tirzepatide — sold as Mounjaro and Zepbound — has become one of the fastest-adopted drugs in modern medicine, with prescriptions written for tens of millions of people globally to manage obesity and type 2 diabetes. For most patients, it's been a genuine breakthrough: impressive weight loss, better blood sugar control, and early cardiovascular benefits. But now, a new analysis is asking a question that prescribers, cardiologists, and patients need to hear: does tirzepatide raise the risk of heart rhythm problems?

[THE DISCOVERY]

Mansouri et al., writing in the Journal of the American Heart Association, performed an updated meta-analysis pooling data from multiple randomized controlled trials of tirzepatide in adults with overweight or obesity. They found that patients taking tirzepatide had higher odds of experiencing overall arrhythmias compared to control groups. The important caveat — and the authors are clear about this — is that the absolute event rates were low. In other words, the relative risk looks elevated, but the actual number of arrhythmia events in these trials was small. The authors explicitly caution against over-interpreting these findings.

[THE SCIENCE BEHIND IT]

This is a meta-analysis: researchers pooled results from multiple RCTs (the gold standard of clinical research) to look for safety signals that individual trials might be too small to detect. That pooling increases statistical power to spot rare events. The key credibility marker here is that the underlying data comes from randomized controlled trials, which are designed to eliminate many confounding factors. The main limitation is that we're working from the abstract only — we don't know exactly how many trials were included, what the specific event rates were, which arrhythmia subtypes were counted, or whether the signal was consistent across trials or driven by one outlier study. It's also worth noting that weight loss itself causes cardiac remodeling, which can independently influence arrhythmia risk — disentangling the drug's direct effect from the effect of weight change is methodologically tricky.

[WHO THIS HELPS]

This finding is immediately relevant to clinicians prescribing tirzepatide — particularly cardiologists, endocrinologists, and primary care providers managing patients who already have risk factors for atrial fibrillation: older adults, people with hypertension or structural heart disease, and those with prior arrhythmia history. For these patients, the risk-benefit calculation may warrant a more explicit discussion. For the vast majority of otherwise healthy adults taking tirzepatide for obesity or diabetes, the absolute risk remains low — but "low" and "zero" are different things.

[THE REAL-WORLD IMPACT]

If this arrhythmia signal is confirmed in larger, longer-term cardiovascular outcome trials, the most likely near-term consequence is updated prescribing information recommending closer cardiac monitoring for high-risk patients — not a contraindication, but a more nuanced conversation at the prescriber level. It could also influence how regulators around the world assess label updates. For already-prescribed patients, this data does not suggest stopping the drug — the authors explicitly say event rates were low and findings should be interpreted cautiously. What may change is the monitoring protocol: baseline ECG in at-risk patients, more frequent check-ins for those with known arrhythmia predisposition.

[WHAT WE STILL DON'T KNOW]

The most pressing unanswered question is whether this is a class effect — does semaglutide (Ozempic/Wegovy) show the same signal? — or specific to tirzepatide's dual GIP/GLP-1 mechanism. We also don't know which arrhythmia subtypes are involved (atrial fibrillation specifically? other rhythm disturbances?), what the absolute event numbers were, or whether longer-term follow-up changes the picture. Large cardiovascular outcome trials (like SURMOUNT-CVOT) will eventually provide clearer answers, but those results may be years away.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate — RCT-based meta-analysis is credible, but low event rates and limited abstract data temper certainty
• Translation Speed: 2–5 years for label clarification; immediate for prescriber awareness
• Barrier Analysis:
  • Regulatory: FDA and EMA will likely review this analysis in the context of ongoing label surveillance
  • Reimbursement: No impact expected
  • Awareness: Prescribers need to be proactively educated — arrhythmia monitoring is not currently a standard part of tirzepatide initiation conversations
  • Equity: Tirzepatide costs ~$1,000+/month without insurance; the patients most at cardiovascular risk are often the least likely to have optimal access

[CALL TO ACTION / CLOSING]

Tirzepatide is changing lives for millions of patients — and that story isn't changing. But any drug prescribed at this scale needs continuous, rigorous safety scrutiny, and that's exactly what this analysis provides. For patients on tirzepatide who have heart rhythm concerns, the message is clear: talk to your doctor — not because this drug is dangerous, but because good medicine means staying informed.

---

---

[HOOK]

A decade ago, oncologists had chemotherapy, radiation, and a handful of targeted drugs. Today, the cancer pharmacy has exploded with a new class of weapons that don't just kill tumors — they find them, tag them, and deliver payloads with near-surgical precision. We're talking about antibody-drug conjugates and bispecific antibodies, two of the hottest platforms in oncology. A new review in the Journal of Hematology & Oncology maps the entire landscape — and the picture it paints shows we are in the middle of a genuine revolution in how cancer is treated.

[THE DISCOVERY]

Lou and Lyu synthesized pivotal clinical data across antibody-drug conjugates (ADCs) — think trastuzumab deruxtecan in HER2+ cancers — and bispecific antibodies (bsAbs) — think blinatumomab in leukemia or teclistamab in myeloma. These aren't just incremental improvements over old drugs. ADCs work like guided missiles: an antibody finds a cancer cell, locks on, and delivers a toxic payload directly inside it, sparing normal tissue. Bispecifics are two-armed antibodies that grab a cancer cell with one hand and an immune cell with the other, physically forcing the immune system to attack. The review draws a roadmap showing where these tools are most effective, where the evidence is strongest, and what questions remain unresolved.

[THE SCIENCE BEHIND IT]

This is a review and meta-analysis of existing clinical trial data — it doesn't generate new evidence, but it organizes and weighs what exists. The Journal of Hematology & Oncology is a high-impact, peer-reviewed journal where such synthesis carries genuine clinical weight. The major strength is breadth: covering both hematologic malignancies (leukemia, lymphoma, myeloma) and solid tumors in a single framework is genuinely useful for oncologists who see mixed patient panels. The main limitation is that review-level synthesis can oversimplify heterogeneous trial populations and doesn't resolve the head-to-head comparison questions clinicians actually face day-to-day: which ADC in which HER2-low patient? Which bispecific after CAR-T failure?

[WHO THIS HELPS]

Medical oncologists, hematologists, and pharmacists working in cancer centers will find this most directly useful. But the ripple effects touch patients across hematologic cancers — multiple myeloma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia — and solid tumors including HER2+ breast cancer, gastric cancer, urothelial cancer, and others. Patients who have exhausted standard therapies are often the most likely to encounter these agents in the clinic or in trials.

[THE REAL-WORLD IMPACT]

Several of the agents discussed are already FDA-approved and in active clinical use. This review's roadmap function is its primary contribution: it helps clinicians sequence these agents rationally, identify where biomarker testing (HER2 expression, CD38 levels, etc.) is required before prescribing, and understand which combinations are being tested. It also highlights unresolved questions — including drug resistance mechanisms, optimal sequencing after prior therapy, and toxicity management (bystander toxicity from ADC payload, cytokine release from bispecifics) — that will shape clinical trial design in the next 2–5 years.

[WHAT WE STILL DON'T KNOW]

The field's biggest open questions are: How do we sequence these agents optimally? What happens when tumors become resistant to one ADC — do other ADCs still work? Can bispecifics be safely combined with CAR-T, and who benefits most from each? How do we manage cumulative toxicity in patients who receive multiple antibody-based therapies over time? And critically — how do we make these therapies accessible globally, given their extraordinary cost?

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High — for agents already approved and in use; Moderate — for emerging combinations and platforms
• Translation Speed: 2–5 years for newer agents and combinations; immediate for already-approved therapies
• Barrier Analysis:
  • Regulatory: Multiple approvals already secured; ongoing trials will expand indications
  • Reimbursement: ADCs and bispecifics cost $10,000–$30,000+ per month; insurance coverage is the most significant access barrier
  • Infrastructure: Bispecific administration requires specialized settings due to cytokine release risk; not all community oncology centers are equipped
  • Equity: Profound — these transformative agents are largely inaccessible outside high-income countries; this is the central unresolved equity challenge in modern oncology

[CALL TO ACTION / CLOSING]

Antibody-based cancer therapies are no longer the future of oncology — they are the present. The challenge now is ensuring that the patients who need them most, wherever they live, can actually access them.

---

---

[HOOK]

Few topics in oncology generate as much patient interest — and as much scientific ambivalence — as vitamin C. For decades, patients have asked their oncologists about high-dose intravenous vitamin C, drawn by compelling biological rationale and anecdotal reports. Now a systematic review takes a hard look at the evidence. The answer is nuanced: there's real biological plausibility, some clinical signal, but a field still waiting for the definitive trial.

[THE DISCOVERY]

Singh et al. conducted a systematic review of high-dose vitamin C — specifically intravenous administration at pharmacological doses far above what oral supplementation can achieve — in cancer treatment. At these doses, vitamin C behaves differently than at nutritional levels: it can generate hydrogen peroxide in the tumor microenvironment, act as a pro-oxidant rather than an antioxidant, and potentially sensitize cancer cells to chemotherapy or radiation. The review concludes that future research should focus on optimizing dosing protocols, identifying predictive biomarkers (which patients are likely to respond), and developing combination approaches. Translation: promising, but not ready for routine clinical use.

[THE SCIENCE BEHIND IT]

A systematic review is a structured synthesis of existing literature — a step up from a narrative review, but it doesn't generate new clinical data. The honest assessment here requires some candor: high-dose IV vitamin C has been studied since Linus Pauling's era, and despite decades of interest, it has not broken through into standard oncology practice. This review appears in the Indian Journal of Clinical Biochemistry, a regional journal with more modest impact than the flagship oncology publications in this batch. The key finding — that protocols need optimization and biomarkers need validation — is essentially the same conclusion prior reviews have reached. That said, the field is evolving: KRAS-mutant cancers and glucose-6-phosphate dehydrogenase (G6PD) deficiency status are emerging as potential predictive biomarkers, and combination with PARP inhibitors is an active area of investigation.

[WHO THIS HELPS]

If the field matures, the beneficiaries would be cancer patients seeking tolerable adjunctive therapies — particularly those who have already completed standard treatment and are seeking options to reduce recurrence risk. Patients with KRAS-mutant colorectal or pancreatic cancer may be an early priority population given mechanistic data. For now, the main benefit goes to researchers and clinicians trying to understand the current state of play.

[THE REAL-WORLD IMPACT]

Right now, this review does not change clinical practice. High-dose IV vitamin C is administered in some integrative oncology settings, but it is not a standard-of-care recommendation from ASCO, ESMO, or NCCN. If the field produces a positive randomized trial with a defined biomarker-selected population, that would change — but we're not there yet. The practical near-term message: patients asking about vitamin C should be counseled that it may be safe as an adjunct (it has a favorable toxicity profile) but has not been shown to improve survival in well-powered trials.

[WHAT WE STILL DON'T KNOW]

The most fundamental unknown is whether the biological signals seen in preclinical models and small pilot trials translate into meaningful survival benefit in well-powered phase 3 trials with biomarker-selected patients. Optimal dosing frequency, duration, and combination partners are all unresolved. G6PD-deficient patients should not receive high-dose IV vitamin C — but screening for this enzyme deficiency before administration is not yet standard.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Low-to-Moderate — biological rationale is solid; clinical evidence remains insufficient
• Translation Speed: 5–10 years minimum, contingent on positive biomarker-selected RCTs
• Barrier Analysis:
  • Regulatory: No approved indication; would require positive phase 3 data
  • Reimbursement: IV vitamin C is inexpensive but requires infusion center infrastructure; not reimbursed as a cancer treatment in most systems
  • Cost: Paradoxically, low cost makes it commercially unattractive for pharmaceutical investment — this may be why definitive trials haven't been funded
  • Equity: If effective, relatively accessible due to low drug cost; access barriers would be in delivery infrastructure
  • Awareness: Patients are already highly aware; clinical adoption lags scientific understanding

[CALL TO ACTION / CLOSING]

High-dose vitamin C isn't snake oil — but it isn't proven medicine yet either. The next step the field genuinely needs isn't another review: it's a well-funded, biomarker-stratified phase 3 trial. Until then, patient curiosity and clinician honesty about uncertainty are the best tools we have.